Liontrust Investment Partners LLP Has $89 Million Holdings in Waters Corporation $WAT

Posted by on Jul 31st, 2026

Liontrust Investment Partners LLP raised its holdings in Waters Corporation (NYSE:WAT – Free Report) by 5,156.0% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 298,855 shares of the medical instruments supplier’s stock after buying an additional 293,169 shares during the period. Liontrust Investment Partners LLP’s holdings in Waters were worth $88,999,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Anchor Investment Management LLC bought a new stake in Waters in the 1st quarter valued at $27,000. Resources Management Corp CT ADV acquired a new stake in Waters during the 1st quarter valued at $27,000. Zions Bancorporation National Association UT boosted its position in Waters by 121.2% during the fourth quarter. Zions Bancorporation National Association UT now owns 73 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 40 shares during the period. Vision Retirement LLC acquired a new position in shares of Waters in the first quarter valued at $29,000. Finally, Bollard Group LLC acquired a new position in shares of Waters in the first quarter valued at $29,000. 94.01% of the stock is owned by institutional investors and hedge funds.

Waters Stock Up 0.4%

WAT stock opened at $381.12 on Friday. Waters Corporation has a fifty-two week low of $275.05 and a fifty-two week high of $414.15. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.79 and a quick ratio of 1.13. The stock has a market capitalization of $37.42 billion, a price-to-earnings ratio of 48.43, a PEG ratio of 2.29 and a beta of 1.20. The business’s fifty day moving average price is $368.60 and its two-hundred day moving average price is $345.25.

Waters (NYSE:WAT – Get Free Report) last announced its earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.31 by $0.39. Waters had a net margin of 11.91% and a return on equity of 15.60%. The company had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.20 billion. During the same quarter in the previous year, the business posted $2.25 earnings per share. Waters’s quarterly revenue was up 91.4% on a year-over-year basis. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. On average, equities analysts anticipate that Waters Corporation will post 14.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $350.00 price objective on shares of Waters in a research report on Thursday, May 7th. Robert W. Baird set a $387.00 price target on shares of Waters in a research note on Wednesday, May 6th. Royal Bank Of Canada assumed coverage on shares of Waters in a report on Wednesday, July 8th. They issued an “outperform” rating and a $435.00 price target on the stock. TD Cowen restated a “hold” rating on shares of Waters in a research report on Wednesday, July 15th. Finally, Wells Fargo & Company boosted their price objective on Waters from $355.00 to $370.00 and gave the stock an “equal weight” rating in a report on Thursday, May 14th. Three investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $401.60.

Get Our Latest Analysis on Waters

About Waters

(Free Report)

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.

Read More

Want to see what other hedge funds are holding WAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Waters Corporation (NYSE:WAT – Free Report).

Institutional Ownership by Quarter for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.